Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

Platelets are essential effector cells in hemostasis. Aside from their role in coagulation,
platelets are now recognized as major inflammatory cells with key roles in the innate and …

Background. Defining the association of non–AIDS-defining events with inflammation and
immune activation among human immunodeficiency virus (HIV)–infected persons with …

Cardiovascular disease is one of the leading causes of morbidity and mortality in people
living with HIV. Several epidemiological studies have shown an increased risk of myocardial …

Cardiovascular disease, and particularly coronary heart disease, is an emerging area of
concern in the HIV population. Since the advent of efficient antiretroviral therapies and the …

Background With the aging of the population living with HIV, the absolute risk of
cardiovascular disease (CVD) is increasing. There is a need to further facilitate the …

The emergence of chronic disease complications in controlled HIV disease has changed the
landscape of HIV clinical care. HIV infection confers an increased cardiovascular disease …

Background: Previous studies of cardiovascular disease (CVD) among HIV-infected
individuals have been limited by the inability to validate and differentiate atherosclerotic type …

Objectives Inversion of the CD 4: CD 8 ratio (< 1) has been identified as a hallmark of
inmmunosenescence and an independent predictor of mortality in the general population …

Background: We sought to clarify the association of HIV infection and immunodeficiency on
myocardial infarction (MI) risk. Methods: We conducted a cohort study from 1996 to 2009 of …